The information does not usually directly identify you, but it can give you a more personalised web experience.
You can accept all, or else manage cookies individually. However, blocking some types of cookies may affect your experience of the site and the services we are able to offer.
You can change your cookies preference at any time by visiting our Cookies Notice page. Please remember to clear your browsing data and cookies when you change your cookies preferences. This will remove all cookies previously placed on your browser.
For more detailed information about the cookies we use, or how to clear your browser cookies data see our Cookies Notice
Manage consent preferences
Strictly necessary cookies
These cookies are necessary for the website to function and cannot be switched off in our systems.
They are essential for you to browse the website and use its features and for us to measure website traffic.
You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. We can't identify you from these cookies.
These help us personalise our sites for you by remembering your preferences and settings. They may be set by us or by third party providers, whose services we have added to our pages. If you do not allow these cookies, then these services may not function properly.
These cookies allow us to count visits and see where our traffic comes from, so we can measure and improve the performance of our site. They help us to know which pages are popular and see how visitors move around the site. The cookies cannot directly identify any individual users.
If you do not allow these cookies we will not know when you have visited our site and will not be able to improve its performance for you.
These cookies may be set through our site by social media services or our advertising partners. Social media cookies enable you to share our content with your friends and networks. They can track your browser across other sites and build up a profile of your interests. If you do not allow these cookies you may not be able to see or use the content sharing tools.
Advertising cookies may be used to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but work by uniquely identifying your browser and internet device. If you do not allow these cookies, you will still see ads, but they won't be tailored to your interests.
Around a third of all currently approved drugs target G protein-coupled receptors (GPCRs), making these receptors the most successful drug target in history. Our research is focused on the structure and function of GPCRs and understanding the signalling pathways that are important for different physiological and pathophysiological responses.OVERVIEWGPCRs are the largest family of cell surface receptors and are involved in the regulation of nearly every mammalian cellular response. Around a
Around a third of all currently approved drugs target G protein-coupled receptors (GPCRs), making these receptors the most successful drug target in history. Our research is focused on the structure and function of GPCRs and understanding the signalling pathways that are important for different physiological and pathophysiological responses.
GPCRs are the largest family of cell surface receptors and are involved in the regulation of nearly every mammalian cellular response. Around a third of all currently approved drugs target GPCRs, making these receptors the most successful drug target in history.
Our research is focused on the structure and function of GPCRs and understanding the signalling pathways that are important for different physiological and pathophysiological responses. We employ wide-ranging and multi-disciplinary approaches to take a ‘molecule to behaviour’ approach to understand, validate and then translate therapeutic opportunities by targeting trans-plasma membrane and intracellular signalling pathways. We identify unique small molecule ligands that modulate cellular signalling cascades and exploit these to define both underpinning biology and their effects on disease progression and remission.
We have driven understanding and therapeutic validation of previously poorly understood and ‘hard to target’ G protein-coupled receptors that are activated by metabolic intermediates, particularly fatty acids of varying chain length. We are established as ‘world-leading’ in areas at the interface so created between metabolism and immunity. This has resulted in ‘spin out’ in 2015 of the company Caldan Therapeutics, which garnered £4.5 million in Series A funding, and in Milligan being a finalist in the 2016 BBSRC ‘Innovator of the Year’ competition. Moreover, our expertise in this area has resulted in the establishment of new links to companies including Heptares Therapeutics and Galapagos NV, as well as consolidating links to the pharmaceutical giant AstraZeneca, resulting in enhanced funding and joint publications.
By linking small molecule ligands, the new wealth of information on structural characteristics of G protein-coupled receptors, and a prion-based model of neurodegenerative disease that displays impaired cognition, Tobin and Bradley have unequivocally established that selective activation of the M1 muscarinic acetylcholine receptor not only improves cognition, a key requirement for any new therapy designed to treat the cognitive decline associated with progression of Alzheimers dementia, but also may actually slow neurodegenerative progression. This work is linked directly to studies being conducted by the pharmaceutical company Eli Lilly. An approach within these studies of generating mouse transgenic ‘knock-in’ lines of receptors modified to act as ‘Designer Receptors Exclusively Activated by Designer Drugs’ has not only been integral to these studies but has inspired the group to broaden this approach to the type of ‘hard to target’ G protein-coupled receptors, a concept developed and reduced to practice by Hudson and Milligan for free fatty acid receptor 2.
The University of Glasgow is one of four ancient universities in Scotland, founded back in 1451.
Alumni include seven Nobel Prize winners, Scotland’s First Minister and a Prime Minister, while Albert Einstein gave a lecture on the theory of relativity there back in 1933.
The university has over 7,000 postgraduate students from 140 countries around the world, taking up taught and research degrees. Study options vary from Financial Economics to European Studies.
The university consists of four colleges:
College of Arts
College of Medical, Veterinary and Life Sciences
College of Science and Engineering
College of Social Sciences
There are three campuses making up the university. Gilmorehill Campus – this is the main campus and it centres on a grand neo-gothic building, with modern facilities and stunning views across the city.
Where you'll study
The Fraser Building
65 Hillhead Street
Glasgow, City Of